Prof Naveed SattarAcademic

Biography

Naveed Sattar is Professor of Cardiometabolic Medicine in the School of Cardiovascular & Metabolic Health at the University of Glasgow, where he has held a professorial chair since 2005. He is also an Honorary Consultant in Metabolic Medicine at Glasgow Royal Infirmary, where he co-leads a cardiovascular disease prevention clinic. His research focuses on the causes, prevention and management of diabetes, obesity and heart disease, encompassing epidemiology, biomarkers, randomised trials and national guidelines. He has contributed to trials including DIRECT, UPBEAT and EUROFIT, and to multiple pharmaceutical trials of newer diabetes and weight-loss agents. In November 2023 he was appointed Chair of the UK Government's Obesity Healthcare Goals Programme, tasked with accelerating medical innovation to improve long-term outcomes for people living with obesity. He is frequently quoted in UK media on GLP-1 weight-loss drugs, obesity policy and cardiovascular risk.

References

1. 1.Professor Naveed Sattar – University of Glasgow Staff Profile — Current role title, school, office address (G12 8TA), career history, ORCID
2. 2.Professor Naveed Sattar appointed UK Government Obesity Mission Chair — Appointment as UK Government Obesity Healthcare Goals Programme Chair in November 2023
3. 3.Professor Naveed Sattar awarded the Diabetes UK 2023 Banting Memorial Lecture — Banting Memorial Lecture award and its significance as the highest Diabetes UK honour
4. 4.Professor Naveed Sattar awarded the Edwin Bierman Award – University of Glasgow — Edwin Bierman Award; Honorary Consultant role at Glasgow Royal Infirmary; fellowship credentials
5. 5.Professor Naveed Sattar – Association for the Study of Obesity

Expertise

Cited on

• Hospital discharge / bed-blocking
• Mental health
• Diabetes

Stated areas of expertise

• Cardiometabolic disease
• Obesity and weight-loss drug policy
• Type 2 diabetes prevention and treatment
• Cardiovascular risk and epidemiology
• GLP-1 receptor agonist trials
• National clinical guidelines

Notable achievements

• Awarded the Diabetes UK 2023 Banting Memorial Lecture – the highest award bestowed by Diabetes UK – in recognition of his outstanding contribution to research into diabetes, obesity and heart disease. Source ↗
• Appointed Chair of the UK Government's Obesity Healthcare Goals Programme in November 2023, leading efforts to accelerate pharmaceutical and digital innovations for obesity in partnership with NIHR. Source ↗
• Awarded the Edwin Bierman Award by the American Diabetes Association in honour of outstanding scientific achievement in the prevention and treatment of macrovascular complications. Source ↗
• Has published over 1,300 papers and has been cited more than 230,000 times (Google Scholar), placing him in the top 1% of the field in clinical medicine. Source ↗
• Chaired the SIGN obesity and CVD prevention guideline committee, and served on the ESC Task Force developing 2023 guidelines on diabetes and cardiovascular disease. Source ↗

What they’ve said

• “This is very good news and stems directly from high-quality trial evidence. We now have medicines that not only reduce heart attacks, strokes and peripheral arterial disease but also simultaneously lead to meaningful weight loss – which in turn lowers the risk of many weight‑related conditions.”

  professor of cardiometabolic medicine at the University of Glasgow · Hospital discharge / bed-blocking · 27 Aug 2026 · NHS England to offer weight-loss drugs to 1.2m people to reduce risk of heart attacks and strokes ↗

• “Caffeine does a multitude of things, some which may be beneficial, some which may be harmful, and the net effect can never be estimated until you do a randomised trial.”

  Professor of cardiometabolic medicine at the University of Glasgow · Mental health · 27 Aug 2026 · A couple of teas or coffees a day could lower risk of dementia, scientists say ↗

• “Overall, this work represents a thoughtful attempt to move towards more holistic risk prediction across multiple obesity‑related conditions. But substantial further development and validation will be required before such an approach can be translated into routine clinical practice.”

  professor of cardiometabolic medicine at the University of Glasgow · Hospital discharge / bed-blocking · 27 Aug 2026 · UK researchers develop tool to identify people most at risk of obesity-related diseases ↗

Source references

1. NHS England to offer weight-loss drugs to 1.2m people to reduce risk of heart attacks and strokestheguardian.com · 27 Aug 2026
2. A couple of teas or coffees a day could lower risk of dementia, scientists saytheguardian.com · 27 Aug 2026
3. UK researchers develop tool to identify people most at risk of obesity-related diseasestheguardian.com · 27 Aug 2026
4. New GLP-1 pill helps patients lose up to 8% of body weight, trial showstheguardian.com · 27 Aug 2026
5. Muscle growth drug ‘could reduce loss of lean tissue’ when using slimming jabstheguardian.com · 27 Aug 2026

Contact & links

• Staff pagehttps://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/naveedsattar/
• ORCIDhttps://orcid.org/0000-0002-1604-2593published here ↗
• LinkedInhttps://uk.linkedin.com/in/naveed-sattar-12653041

Organisational contact points only, each taken from a page the organisation publishes itself. No personal or direct contact details are held or shown.